GILLIS JONATHAN 4
4 · MapLight Therapeutics, Inc. · Filed Apr 29, 2026
Research Summary
AI-generated summary of this filing
MapLight (MPLT) CAAO/PAO Jonathan Gillis Sells Shares
What Happened
Jonathan Gillis, MapLight Therapeutics’ Chief Accounting and Principal Accounting Officer (CAAO/PAO), sold a total of 69,835 shares in multiple open-market transactions on April 27–28, 2026 for aggregate proceeds of $2,087,688. The sales were reported as Rule 10b5-1 plan trades and were reported on a Form 4 filed April 29, 2026. Individual transactions reported:
- 7,914 shares at $28.94 — $229,031 (sold across prices $28.27–$29.25)
- 29,623 shares at $29.60 — $876,841 (sold across prices $29.27–$30.25)
- 14,363 shares at $30.46 — $437,497 (sold across prices $30.27–$30.64)
- 17,235 shares at $30.33 — $522,738 (sold across prices $29.755–$30.71)
- 700 shares at $30.83 — $21,581 (sold across prices $30.81–$30.86)
Key Details
- Transaction type: S = Sale (open-market / private sale) under a Rule 10b5-1 trading plan (plan adopted Dec 26, 2025).
- Dates: April 27 and April 28, 2026; Form 4 filed April 29, 2026 (appears timely).
- Total shares sold: 69,835 for total proceeds of $2,087,688 (reported as weighted-average prices with ranges per footnotes).
- Shares owned after transaction: Not disclosed in the provided excerpt of the filing.
- Footnotes: Several weighted-average price footnotes list the price ranges for the multiple executions; the filer offers to provide a breakdown of shares sold at each price on request.
Context
- Sales executed under a 10b5-1 plan are pre-arranged and typically indicate planned disposition rather than ad hoc trading; they do not by themselves signal the filer’s current view on the company.
- For retail investors, purchases generally carry more informational weight than routine, planned insider sales—but monitoring insider activity over time can provide additional context.
Insider Transaction Report
Form 4
GILLIS JONATHAN
CAO and Interim CFO
Transactions
- Sale
Voting Common Stock
[F1][F2]2026-04-27$28.94/sh−7,914$229,031→ 243,140 total - Sale
Voting Common Stock
[F1][F3]2026-04-27$29.60/sh−29,623$876,841→ 213,517 total - Sale
Voting Common Stock
[F1][F4]2026-04-27$30.46/sh−14,363$437,497→ 199,154 total - Sale
Voting Common Stock
[F1][F5]2026-04-28$30.33/sh−17,235$522,738→ 181,919 total - Sale
Voting Common Stock
[F1][F6]2026-04-28$30.83/sh−700$21,581→ 181,219 total
Footnotes (6)
- [F1]This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 26, 2025.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.27 to $29.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.27 to $30.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.27 to $30.64 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.755 to $30.71 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.81 to $30.86 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Signature
/s/ Kristopher L. Hanson, Attorney-in-Fact|2026-04-29